Literature DB >> 24682714

Natural autoantibodies to Fcγ receptors in intravenous immunoglobulins.

Hicham Bouhlal1, Denis Martinvalet, Jean-Luc Teillaud, Catherine Fridman, Michel D Kazatchkine, Jagadeesh Bayry, Sébastien Lacroix-Desmazes, Srini V Kaveri.   

Abstract

A considerable progress has been achieved in the comprehension of the cellular and molecular mechanisms that account for the therapeutic benefit of intravenous immunoglobulin (IVIg) in several autoimmune and inflammatory conditions. However, the precise mechanisms responsible for such a wide range of biological activities have not been proven unambiguously. A wide range of specificities have been identified within IVIg including idiotypes of immunoglobulins, T cell receptor, HLA molecules, several cell surface molecules of immunological importance such as CD4, CD5, Fas, BAFF, cytokines and cytokine receptors, chemokine receptors, CD40 among others. Here we identify and characterize the natural autoantibodies of IgG isotype directed against the human Fc receptors. We show that the F(ab')2 of IVIg recognize the FcγRIII (CD16) and FcγRII (CD32). Interestingly, the immunopurified anti-FcγIII and anti-FcγII antibodies isolated from IVIg bind soluble and membrane-bound FcR and inhibit rosette formation. Altogether, these results along with previous reports provide pointers on the existence of functionally relevant natural autoantibodies towards a wide range of self-motifs that may participate in regulation of the immune response. Their presence in the therapeutic immunoglobulin preparations may explain at least in part, the beneficial effect of IVIg in autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24682714     DOI: 10.1007/s10875-014-0019-2

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  30 in total

1.  Autoantibodies to coagulation factors.

Authors:  J-M R Saint-Remy
Journal:  Haemophilia       Date:  2010-05       Impact factor: 4.287

Review 2.  Use of intravenous immunoglobulin G (IVIG).

Authors:  R John Looney; Jennifer Huggins
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

Review 3.  Intravenous immunoglobulins--understanding properties and mechanisms.

Authors:  A Durandy; S V Kaveri; T W Kuijpers; M Basta; S Miescher; J V Ravetch; R Rieben
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

Review 4.  IgG Fc receptors.

Authors:  J V Ravetch; S Bolland
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

5.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

Authors:  A Samuelsson; T L Towers; J V Ravetch
Journal:  Science       Date:  2001-01-19       Impact factor: 47.728

Review 6.  Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease.

Authors:  Vincent R Bonagura
Journal:  J Clin Immunol       Date:  2012-12-28       Impact factor: 8.317

7.  Granulocyte-macrophage colony-stimulating factor induces sequential activation and deactivation of binding via a low-affinity IgG Fc receptor, hFc gamma RII, on human eosinophils.

Authors:  L Koenderman; S W Hermans; P J Capel; J G van de Winkel
Journal:  Blood       Date:  1993-05-01       Impact factor: 22.113

8.  Pivotal involvement of Fcgamma receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1.

Authors:  Irene Dunn-Siegrist; Olivier Leger; Bruno Daubeuf; Yves Poitevin; Fabien Dépis; Suzanne Herren; Marie Kosco-Vilbois; Yann Dean; Jérôme Pugin; Greg Elson
Journal:  J Biol Chem       Date:  2007-10-05       Impact factor: 5.157

Review 9.  Natural and recombinant soluble low-affinity Fc gamma R: detection, purification, and functional activities.

Authors:  J L Teillaud; C Bouchard; A Astier; C Teillaud; E Tartour; J Michon; A Galinha; J Moncuit; N Mazières; R Spagnoli
Journal:  Immunomethods       Date:  1994-02

10.  Autoimmune mice make anti-Fc gamma receptor antibodies.

Authors:  P Boros; J M Chen; C Bona; J C Unkeless
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

View more
  10 in total

1.  Recombinant Proteins and Monoclonal Antibodies.

Authors:  Roy Jefferis
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

Review 2.  Mechanisms of action of Ig preparations: immunomodulatory and anti-inflammatory effects.

Authors:  Andrea Matucci; Enrico Maggi; Alessandra Vultaggio
Journal:  Front Immunol       Date:  2015-01-12       Impact factor: 7.561

Review 3.  Control of cytokine production by human fc gamma receptors: implications for pathogen defense and autoimmunity.

Authors:  Lisa T C Vogelpoel; Dominique L P Baeten; Esther C de Jong; Jeroen den Dunnen
Journal:  Front Immunol       Date:  2015-02-24       Impact factor: 7.561

Review 4.  On the dark side of therapies with immunoglobulin concentrates: the adverse events.

Authors:  Peter J Späth; Guido Granata; Fabiola La Marra; Taco W Kuijpers; Isabella Quinti
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

Review 5.  Intravenous Immunoglobulin and Immunomodulation of B-Cell - in vitro and in vivo Effects.

Authors:  Milica Mitrevski; Ramona Marrapodi; Alessandro Camponeschi; Filomena Monica Cavaliere; Cristina Lazzeri; Laura Todi; Marcella Visentini
Journal:  Front Immunol       Date:  2015-01-22       Impact factor: 7.561

Review 6.  HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs.

Authors:  Mepur H Ravindranath
Journal:  J Immunol Res       Date:  2017-05-28       Impact factor: 4.818

7.  Monomeric Immunoglobulin A from Plasma Inhibits Human Th17 Responses In Vitro Independent of FcαRI and DC-SIGN.

Authors:  Chaitrali Saha; Mrinmoy Das; Veerupaxagouda Patil; Emmanuel Stephen-Victor; Meenu Sharma; Sandra Wymann; Monika Jordi; Cédric Vonarburg; Srini V Kaveri; Jagadeesh Bayry
Journal:  Front Immunol       Date:  2017-03-14       Impact factor: 7.561

8.  Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system.

Authors:  Cristina Segú-Vergés; Silvia Caño; Elisabeth Calderón-Gómez; Helena Bartra; Teresa Sardon; Srini Kaveri; José Terencio
Journal:  Front Immunol       Date:  2022-09-30       Impact factor: 8.786

Review 9.  The Homophilic Domain - An Immunological Archetype.

Authors:  Heinz Kohler; Jagadeesh Bayry; Srinivas V Kaveri
Journal:  Front Immunol       Date:  2016-03-21       Impact factor: 7.561

10.  Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?

Authors:  Laetitia Sordé; Sebastian Spindeldreher; Ed Palmer; Anette Karle
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.